Amgen Inc.

Daniel Martin Retz

Gang Liu

Adrian Leonard Smith

Nick A Paras

Elizabeth Rainbeau

Paul Edward Brennan

Jian Jeffrey Chen

Joseph L Kim

Stephen A Hitchcock

Qi Huang

Elizabeth M Doherty

Thomas Nixey

Jiawang Zhu

Frenel Fils De Morin

Frenel Fils DeMorin

Jeffrey Petkus

Fenel F Fils

Frenel Fils Demorin

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein Ris and A, A, A, A, X, Z, Z', R, R, R, R, Rand Rare defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

Substituted pyrimidine compounds as RAF inhibitors and methods of use

The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.

Aminopyrimidine compounds and methods of use

Growing community of inventors

Yorba Linda, CA, United States of America

Daniel Martin Retz